TY - JOUR
T1 - Complying with the guideline for quality and equivalence for topical semisolid products
T2 - The case of clotrimazole cream
AU - Alves, Teresa
AU - Arranca, Daniel
AU - Martins, Ana
AU - Ribeiro, Helena
AU - Raposo, Sara
AU - Marto, Joana
N1 - Publisher Copyright:
© 2021, MDPI AG. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Semisolids constitute a significant proportion of topical pharmaceutical dosage forms available on the market, with creams being considered profitable systems for releasing active substances into the skin. This work aimed at the development of a generic Clotrimazole topical cream, based on the assumptions that assist the development of such formulations. First, the critical parameters to obtain a final formulation as similar as possible to the reference product were defined. Then, the percentages of cetyl palmitate and octyldodecanol were identified as critical variables and chosen for optimization in further studies. A “quality by design” approach was then used to identify the effect of process variability on the structural and functional similarity (Q3) of the generic product qualitatively (Q1) and quantitatively (Q2). A two‐factor central composite orthogonal design was applied and eleven different formulations were developed and subjected to physicochemical characterization and product performance studies. The results were used to estimate the influence of the two variables in the variation of the responses, and to determine the optimum point of the tested factors, using a design space approach. Finally, an optimized formulation was obtained and analysed in parallel with the reference. The obtained results agreed with the prediction of the chemometric analysis, validating the reliability of the developed multivariate models. The in vitro release and permeation results were similar for the reference and the generic formulations, support-ing the importance of interplaying microstructure properties with product performance and stabil-ity. Lastly, based on quality targets and response constraints, optimal working conditions were suc-cessfully achieved.
AB - Semisolids constitute a significant proportion of topical pharmaceutical dosage forms available on the market, with creams being considered profitable systems for releasing active substances into the skin. This work aimed at the development of a generic Clotrimazole topical cream, based on the assumptions that assist the development of such formulations. First, the critical parameters to obtain a final formulation as similar as possible to the reference product were defined. Then, the percentages of cetyl palmitate and octyldodecanol were identified as critical variables and chosen for optimization in further studies. A “quality by design” approach was then used to identify the effect of process variability on the structural and functional similarity (Q3) of the generic product qualitatively (Q1) and quantitatively (Q2). A two‐factor central composite orthogonal design was applied and eleven different formulations were developed and subjected to physicochemical characterization and product performance studies. The results were used to estimate the influence of the two variables in the variation of the responses, and to determine the optimum point of the tested factors, using a design space approach. Finally, an optimized formulation was obtained and analysed in parallel with the reference. The obtained results agreed with the prediction of the chemometric analysis, validating the reliability of the developed multivariate models. The in vitro release and permeation results were similar for the reference and the generic formulations, support-ing the importance of interplaying microstructure properties with product performance and stabil-ity. Lastly, based on quality targets and response constraints, optimal working conditions were suc-cessfully achieved.
KW - Generic medicine
KW - Pharmaceutical development
KW - Quality by design
KW - Rheology
KW - Topical delivery system
UR - http://www.scopus.com/inward/record.url?scp=85104616157&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics13040555
DO - 10.3390/pharmaceutics13040555
M3 - Article
AN - SCOPUS:85104616157
SN - 1999-4923
VL - 13
JO - Pharmaceutics
JF - Pharmaceutics
IS - 4
M1 - 555
ER -